Vepsitamab

N/A

Report date: 2026/03/19 16:52:46

Base Information

Drug NameVepsitamab
Drug Alias NameMUC17 HLE BiTEAMG-199
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > T cell engagers
Mechanisms of ActionAnti-CD3T lymphocytes stimulantsAnti-MUC17
TargetsT cell surface glycoprotein CD3Mucin-17
Therapy Area/IndicationsStomach NeoplasmsEsophageal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaIND
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesBeOne Medicines LtdAmgen IncAmgen Biotechnology Consultation (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsStomach NeoplasmsEsophageal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBank